High-risk prostate cancer patients benefit from perioperative apalutamide therapy
High-risk localized and locally advanced prostate cancer patients treated with apalutamide – a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) – plus hormone therapy before and after prostate cancer surgery…